Cell-Based Cancer Cure
for Solid Tumors and Hematological Cancers

Cellicure provides innovative, cell-based immunotherapy technologies, customized treatment regimens and real world solutions to solve the current unmet therapeutic needs created by cancer, infectious diseases, and chronic inflammatory diseases.

Our Technologies

CAR-NK

Cellicure has developed patented CAR-NK technologies that have overcome the many challenges that arise from using NK cells and NK specific CARs for immunotherapy.

csCAR-NK

Cellicure’s complete signaling CAR (csCAR-NK) enhances activation signaling and overcomes the inhibitory signaling barrier, resulting in complete activation of NK cells.

cytokine-free reNKTM

Cellicure’s cytokine-free renewable NK (reNKTM) platform enables the long-term renewability of NK cells that does not require continual cytokine stimulation.

Effic NKTM

Cellicure’s NK expansion system (Effic-NKTM) simplifies the human NK expansion process, providing higher efficiency and lower cost.

CAR-T

Cellicure’s CAR-T technology provides CAR-T cells with improved persistence abilities, rapidly accelerating immunotherapy efficiency.

nCAR-TTM Platforms

Cellicure’s nCAR-TTM platform provides CAR-T cells with higher persistence, improving the immunotherapy efficiency of CAR-T cells.